One of the major breakthrough in the treatment of tumor patients during the last decade was the introduction of blocking antibodies against immune checkpoint (ICP) receptors, especially against CTLA-4 and PD1, leading to long-term tumor control in melanoma, NSCLC and renal cell carcinoma patients. Here, CTLA4 is linked to hereditary clear cell renal cell carcinoma.